Overview

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
Phase:
Phase 3
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Mifepristone